Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is positioning itself to address growing demand for quality assurance and transparency in the emerging regulated peptide market through a strategy focused on dependable supply, documented traceability, independent third-party verification and science-based product development. As U.S. regulators consider expanding access to certain compounded peptides while raising concerns about product purity, impurities and safety, the company plans to establish a U.S.-based, GMP-standard supply network using qualified manufacturers and independent laboratories to verify peptide identity and quality. Led by CEO Dr. J. David Warren, a medicinal and peptide chemist with more than 20 years of experience, 17 issued patents and more than 50 publications, Adaptogenics also intends to pursue research programs focused initially on mitochondrial biology and the resolution of inflammation, with the goal of developing proprietary assets supported by measurable scientific outcomes, defined development milestones and meaningful intellectual property.
To view the full article, visit https://ibn.fm/CX1h9
About Adaptogenics Health Corp.
Adaptogenics is building a science led company focused on identifying, acquiring, designing and advancing proprietary peptide and small molecule programs. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The company will continue its existing nutraceutical operations while evaluating GLP 1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.
NOTE TO INVESTORS: The latest news and updates relating to ADPTare available in the company’s newsroom at https://ibn.fm/ADPT
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN